Clinical Outcome After Hematopoietic Stem Cell Transplantation for SLE
| . | Patient SLE #1 . | |||
|---|---|---|---|---|
| Pretransplant . | 2 mo Posttransplant . | 6 mo Posttransplant . | 12 mo Posttransplant . | |
| SLEDAI score | 37 | 0 | 0 | 0 |
| Hemoglobin (mg/dL) | 6.5 | 10.0 | 12.3 | 12.4 |
| White blood cells/μL | 2,000 | 6,000 | 6,100 | 6,100 |
| Platelets (no./μL) | 100,000 | 240,000 | 215,000 | 235,000 |
| 24-hour urine protien (g) | 3.6 | 0.6 | 0.87 | 0.2 |
| Serum creatinine (mg/dL) | 5.0 | 2.6 | 2.7 | 1.9 |
| C3 (68-164 mg/dL) | 52 low | 100 normal | 114 normal | 113 normal |
| C4 (7-47 mg/dL) | 6 low | 40 normal | 35 normal | 35 normal |
| ANA | 1:320 high | 1:40 normal | 1:40 normal | 1:80 increased |
| Anti–double-stranded DNA | 1:160 high | 1:60 borderline | 1:60 borderline | 1:60 borderline |
| . | Patient SLE #1 . | |||
|---|---|---|---|---|
| Pretransplant . | 2 mo Posttransplant . | 6 mo Posttransplant . | 12 mo Posttransplant . | |
| SLEDAI score | 37 | 0 | 0 | 0 |
| Hemoglobin (mg/dL) | 6.5 | 10.0 | 12.3 | 12.4 |
| White blood cells/μL | 2,000 | 6,000 | 6,100 | 6,100 |
| Platelets (no./μL) | 100,000 | 240,000 | 215,000 | 235,000 |
| 24-hour urine protien (g) | 3.6 | 0.6 | 0.87 | 0.2 |
| Serum creatinine (mg/dL) | 5.0 | 2.6 | 2.7 | 1.9 |
| C3 (68-164 mg/dL) | 52 low | 100 normal | 114 normal | 113 normal |
| C4 (7-47 mg/dL) | 6 low | 40 normal | 35 normal | 35 normal |
| ANA | 1:320 high | 1:40 normal | 1:40 normal | 1:80 increased |
| Anti–double-stranded DNA | 1:160 high | 1:60 borderline | 1:60 borderline | 1:60 borderline |
| . | Patient SLE #24-150 . | ||
|---|---|---|---|
| Pretransplant . | 2 mo Posttransplant . | 6 mo Posttransplant . | |
| SLEDAI score | 32 | 0 | 0 |
| Hemoglobin (mg/dL) | 8.0 | 10.1 | 11.8 |
| Platelets (no./μL) | 135,000 | 236,000 | 242,000 |
| Chest roentograph | Bilateral Infiltrates Alveolar Hemorrhage Vasculitis | Normal | Normal |
| Pulmonary function test, DLCO | 50% predicted | 50% predicted | 50% predicted |
| Serum creatinine (mg/dL) | 1.3 | 1.1 | 1.1 |
| C3 | 62 low | 190 high | 167 normal |
| C4 | 10 normal | 45 normal | 29 normal |
| ANA | 1:1280 high | 1:40 normal | 1:160 increased |
| Anti–double-stranded DNA | 1:320 high | Negative | Negative |
| . | Patient SLE #24-150 . | ||
|---|---|---|---|
| Pretransplant . | 2 mo Posttransplant . | 6 mo Posttransplant . | |
| SLEDAI score | 32 | 0 | 0 |
| Hemoglobin (mg/dL) | 8.0 | 10.1 | 11.8 |
| Platelets (no./μL) | 135,000 | 236,000 | 242,000 |
| Chest roentograph | Bilateral Infiltrates Alveolar Hemorrhage Vasculitis | Normal | Normal |
| Pulmonary function test, DLCO | 50% predicted | 50% predicted | 50% predicted |
| Serum creatinine (mg/dL) | 1.3 | 1.1 | 1.1 |
| C3 | 62 low | 190 high | 167 normal |
| C4 | 10 normal | 45 normal | 29 normal |
| ANA | 1:1280 high | 1:40 normal | 1:160 increased |
| Anti–double-stranded DNA | 1:320 high | Negative | Negative |
The SLEDAI is a measure of activity or inflammation in nine organ systems. It has a theoretical maximum of 105 points. A normal person has a SLEDAI of zero.
Abbreviation: SLEDAI, SLE disease activity index.26
White blood cell count and 24-hour urine protein on SLE patient no. 2 was always normal and is not included in the table.